Drug Approval | December 06, 2024
FDA accepts supplemental Biologics License Application for Roche’s Columvi combination
For people with relapsed or refractory diffuse large B-cell lymphoma
For people with relapsed or refractory diffuse large B-cell lymphoma
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
MedGenome reaffirms its commitment to broaden access to quality and affordable genetic solutions for all
The collaborations will help curate industry focused courses such as Advanced Certification courses for healthcare professionals in Healthcare Marketing, Healthcare Technology and Specialized Clinical Fellowship Level programs with university accreditation
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
This two-day program was attended by 40 doctors & paramedical staff
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
The average time of dilation lasts three to eight hours
This newly set up Centre for bio-analytical testing has already received European Regulatory Authority clearance recently
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
